TOVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Theriva Biologics Inc (TOVX) is not a strong buy for a beginner investor with a long-term focus at this time. While there are some positive developments regarding its VCN-01 therapy and analyst upgrades, the company's financial performance is weak, and the stock's technical indicators and trading trends do not present a compelling entry point. The lack of significant trading signals and the pre-market price decline further support a cautious approach.
The MACD is positive and expanding, suggesting a bullish momentum. However, the RSI is neutral at 68.914, and moving averages are converging, indicating no clear trend. The stock's pre-market price is down 2.47%, and key support and resistance levels suggest limited upside potential in the short term.
Theriva Biologics is advancing its VCN-01 therapy for metastatic pancreatic cancer, with plans for a pivotal Phase 3 trial in collaboration with the FDA and EMA. The stock saw a significant after-hours rise of 79.08% recently, reflecting positive market sentiment for the therapy.
Additionally, hedge funds and insiders show no significant trading trends, and the stock's pre-market price is declining.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped to -$3,506,000, down 21.16% YoY, and EPS fell to -0.12, down 92.45% YoY. Gross margin remained at 0 with no improvement.
Maxim recently upgraded the stock to Buy from Hold with a $1 price target, citing a clearer and more capital-efficient path for VCN-01 in metastatic pancreatic cancer. However, Alliance Global recently lowered its price target from $7 to $4 due to an increase in share count.
